Prostate Cancer
Conditions
Keywords
castrate resistant prostate cancer, metastatic, sipuleucel-T, lymphadenectomy, Excisional lymph node biopsy
Brief summary
This study aims to evaluate patients with metastatic castrate-resistant prostate cancer (mCRPC) undergoing treatment with sipuleucel-T for evidence of treatment-associated immune activation in lymph nodes and peripheral blood.
Detailed description
This is a pilot study of mCRPC patients planning to undergo therapy with sipuleucel-T immunotherapy. Consenting patients will be randomized 3:1 between immediate sipuleucel-T immunotherapy followed by lymph node biopsy (the post-treatment experimental group) or immediate lymph node biopsy followed by sipuleucel-T immunotherapy (the pre-treatment control group). Peripheral blood will be collected before, during, and after treatment with sipuleucel-T and evaluated for evidence of sipuleucel-T induced immune activation. Lymph nodes collected at biopsy will also be evaluated for evidence of sipuleucel-T induced immune activation. Patients will be followed for 3 months for safety and 6 months for disease progression.
Interventions
DRUGSipuleucel-T
PROCEDURELymph Node Biopsy
Sponsors
Duke University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years 2. ECOG performance status 0 or 1 3. Life expectancy of ≥ 6 months 4. Minimally-symptomatic or asymptomatic, castrate-resistant metastatic prostate cancer, as evidenced by all of the following: 1. Histologically-confirmed diagnosis of adenocarcinoma of the prostate 2. Evidence of adequate androgen deprivation, as evidence by one of the following: * Bilateral orchiectomy * Ongoing LHRH agonist (e.g. leuprolide, goserelin) and serum testosterone \<50 ng/dl * Ongoing LHRH antagonist (e.g. degarelix) and serum testosterone \<50 ng/dl 3. Evidence of prostate cancer resistance to castration, as evidenced by one of the following: * 2 consecutive PSA levels that are ≥ 50% above the PSA nadir achieved on ADT and obtained at least 1 week apart * CT or MRI based evidence of disease progression (soft tissue or nodal) according to PCWG2 criteria or RECIST 1.1 criteria, or at least 1 new bone scan lesion as compared to the most immediate prior radiologic studies. 4. Presence of non-visceral metastases on imaging 5. Absence of major symptoms directly attributable to prostate cancer, with the following permissible exceptions: * Ureteral obstruction secondary to pelvic or retroperitoneal lymphadenopathy * Bladder outlet obstruction secondary to locally recurrent prostate cancer 5. Radiographic evidence of lymphadenopathy, defined as a lymph node greater than 1 cm in diameter on axial imaging (CT or MRI or PET/CT) 6. Adequate laboratory parameters 7. A minimum of 4 weeks from any major surgery prior to registration. Coincident standard of care surgery with the research biopsy is permitted during the study.
Exclusion criteria
1. Prior treatment with sipuleucel-T 2. Allergy to any component of sipuleucel-T 3. Inability to undergo leukapheresis 4. History of neuroendocrine variants of prostate cancer, including small cell carcinoma of the prostate 5. Extensive prior surgery/radiation present that would render the biopsy highly complex and the risk of intraoperative injury high 6. Any chronic medical condition requiring daily corticosteroids or other immunosuppressants 7. Solid organ transplantation requiring immunosuppression 8. Visceral (e.g. lung, liver) metastases 9. Known brain metastases 10. History of spinal cord compression 11. Untreated/unstabilized pathologic long bone fractures 12. Other malignancy, except non-melanoma skin cancer, with a ≥ 30% probability of recurrence within 24 months 13. Administration of any investigational therapeutic within 30 days of registration 14. Any condition which, in the opinion of the investigator, would preclude participation in this trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| anti-PA2024 immune response in lymph node-derived leukocytes | Lymph node biopsy, approximately 10 weeks | Proportion of patients with lymph node-derived leukocytes showing anti-PA2024 activity as measured by IFNγ ELISPOT |
| anti-PAP immune response in lymph node-derived leukocytes | Lymph node biopsy, approximately 10 weeks | Proportion of patients with lymph node-derived leukocytes showing anti-PAP activity as measured by IFNγ ELISPOT |
| anti-PA2024 immune response in PBMCs | Baseline | Proportion of patients with PBMC samples showing anti-PA2024 activity as measured by IFNγ ELISPOT at each time point |
| anti-PAP immune response in PBMCs | Baseline | Proportion of patients with PBMC samples showing anti-PAP activity as measured by IFNγ ELISPOT at each time point |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum anti-PA2024 antibody level | Baseline, up to 6 months post-treatment | Describe any relationship between the magnitude of sipuleucel-T induced leukocyte activation observed in tumor-bearing lymph nodes with systemic (i.e. peripheral blood) studies of sipuleucel-T-induced immune activation |
| serum anti-PAP antibody level | Baseline, up to 6 months post-treatment | Describe any relationship between the magnitude of sipuleucel-T induced leukocyte activation observed in tumor-bearing lymph nodes with systemic (i.e. peripheral blood) studies of sipuleucel-T-induced immune activation |
Countries
United States
Outcome results
None listed